A Nasir1, A Lopez, D Boulware, M Malafa, D Coppola. 1. Department of Anatomic Pathology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, Florida 33612-9497, USA.
Abstract
BACKGROUND: Because of clinicopathologic and genetic differences between left-sided colorectal cancer (LSCRC) and right-sided colon cancer (RSCC), cyclooxygenase-2(COX-2) and adenomatous polyposis coli (APC) expression may be of clinical relevance. MATERIALS AND METHODS: Clinicopathologic information for 72 primary colon tumors, 44 left and 28 right, from 72 patients (34 F, 38 M) were analyzed. COX-2 and wild-type APC (W-APC) immunohistochemical expressions were determined for each case. The data were analyzed using the Chi-square test and exact binomial confidence intervals. RESULTS: Overall, 31 out of 44 (70%) LSCRC were W-COX-2 positive vs. 13 out of 28 (46%) RSCC (p-value=0.042). When evaluated independently of the anatomic location, COX-2 expression showed a borderline statistical correlation with the lack of W-APC protein (p-value=0.054). When considering location of tumors, the inverse correlation between COX-2 and W-APC expression became statistically significant (p-value=0.024). CONCLUSION: We report a strong inverse correlation between COX-2 and W-APC expression, with COX-2 being more frequently as expressed in LSCRC. These data may be useful to stratify colorectal cancer patients into right- and left-sided and COX-2 expressor and non-expressor subsets, when evaluating COX-2 inhibitor and other targeted therapies in colon cancer.
BACKGROUND: Because of clinicopathologic and genetic differences between left-sided colorectal cancer (LSCRC) and right-sided colon cancer (RSCC), cyclooxygenase-2(COX-2) and adenomatous polyposis coli (APC) expression may be of clinical relevance. MATERIALS AND METHODS: Clinicopathologic information for 72 primary colon tumors, 44 left and 28 right, from 72 patients (34 F, 38 M) were analyzed. COX-2 and wild-type APC (W-APC) immunohistochemical expressions were determined for each case. The data were analyzed using the Chi-square test and exact binomial confidence intervals. RESULTS: Overall, 31 out of 44 (70%) LSCRC were W-COX-2 positive vs. 13 out of 28 (46%) RSCC (p-value=0.042). When evaluated independently of the anatomic location, COX-2 expression showed a borderline statistical correlation with the lack of W-APC protein (p-value=0.054). When considering location of tumors, the inverse correlation between COX-2 and W-APC expression became statistically significant (p-value=0.024). CONCLUSION: We report a strong inverse correlation between COX-2 and W-APC expression, with COX-2 being more frequently as expressed in LSCRC. These data may be useful to stratify colorectal cancerpatients into right- and left-sided and COX-2 expressor and non-expressor subsets, when evaluating COX-2 inhibitor and other targeted therapies in colon cancer.
Authors: M C Turner; D Becerra; Z Sun; J Watson; K Leung; J Migaly; C R Mantyh; D G Blazer Journal: Tech Coloproctol Date: 2019-06-12 Impact factor: 3.781
Authors: Matilda Holm; Sakari Joenväärä; Mayank Saraswat; Tiialotta Tohmola; Ari Ristimäki; Risto Renkonen; Caj Haglund Journal: Cancer Med Date: 2020-05-26 Impact factor: 4.452
Authors: Donald D Nolting; Michael Nickels; Mohammed N Tantawy; James Y H Yu; Jingping Xie; Todd E Peterson; Brenda C Crews; Larry Marnett; John C Gore; Wellington Pham Journal: Front Oncol Date: 2013-01-03 Impact factor: 6.244
Authors: Hanne Kolsrud Hustoft; Tore Vehus; Ole Kristian Brandtzaeg; Stefan Krauss; Tyge Greibrokk; Steven Ray Wilson; Elsa Lundanes Journal: PLoS One Date: 2014-09-15 Impact factor: 3.240